Q4 EPS Estimate for Pacira BioSciences Decreased by Analyst

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Analysts at Zacks Research cut their Q4 2024 earnings per share estimates for shares of Pacira BioSciences in a note issued to investors on Wednesday, November 27th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.58 for the quarter, down from their prior estimate of $0.62. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.26 per share.

Other equities research analysts also recently issued reports about the company. JPMorgan Chase & Co. restated an "underweight" rating and set a $10.00 price objective (down from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Truist Financial cut Pacira BioSciences from a "buy" rating to a "sell" rating and dropped their price target for the stock from $30.00 to $8.00 in a research note on Tuesday, August 13th. StockNews.com cut shares of Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Monday, August 12th. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Pacira BioSciences in a report on Friday, November 8th. Finally, Jefferies Financial Group lifted their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $23.50.

Pacira BioSciences Price Performance

PCRX traded up $0.69 during trading on Monday, reaching $17.60. 301,386 shares of the stock were exchanged, compared to its average volume of 841,560. The business's 50 day moving average price is $16.46 and its two-hundred day moving average price is $19.76. Pacira BioSciences has a 1 year low of $11.16 and a 1 year high of $35.95. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The company has a market capitalization of $812.59 million, a price-to-earnings ratio of -8.33 and a beta of 0.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its position in Pacira BioSciences by 229.6% in the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock valued at $38,000 after acquiring an additional 932 shares in the last quarter. Park Place Capital Corp purchased a new position in shares of Pacira BioSciences in the second quarter valued at $46,000. Innealta Capital LLC purchased a new stake in shares of Pacira BioSciences during the 2nd quarter valued at about $50,000. nVerses Capital LLC boosted its stake in Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after buying an additional 1,600 shares during the period. Finally, CWM LLC boosted its stake in shares of Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company's stock worth $98,000 after purchasing an additional 5,716 shares during the period. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.